We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Guangzhou Pluslife Biotech Co., Ltd.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Midlife Lipid and Glucose Levels Are Associated With Alzheimer's Disease

By LabMedica International staff writers
Posted on 30 Mar 2022
Print article
Image: Midlife lipid and glucose levels are associated with Alzheimer\'s disease (Photo courtesy of Stanford Blood Center)
Image: Midlife lipid and glucose levels are associated with Alzheimer\'s disease (Photo courtesy of Stanford Blood Center)

Alzheimer's disease (AD) is the fifth leading cause of death among Americans 65 years of age or older, with a prevalence of 5.8 million cases. This number is projected to nearly triple to 14 million people by 2060.

Individuals with AD commonly exhibit features of cerebrovascular disease in combination with amyloid beta (Aβ) and tau neuropathology. Genetic studies of AD have identified common and rare variants associated with AD in genes involved in lipoprotein metabolism and processing related to AD.

Medical Scientists at the Boston University School of Medicine (Boston, MA, USA) and their colleagues looked at the influence of vascular risk factors on incident Alzheimer's dementia over time among Framingham Heart Study Offspring participants, a group that's been evaluated since 1971. A total of 271 participants (167 women, 104 men) diagnosed with Alzheimer's dementia were included in the analysis as cases. Of these, 225 people were without stroke, 24 people had Alzheimer's and stroke, and 24 people had mixed Alzheimer's and vascular dementia. People with a diagnosis of non-Alzheimer's dementia were excluded. Controls included 4,867 cognitively normal participants.

Data on lipid fractions, glucose, blood pressure, BMI, and smoking were obtained prospectively from participants across nine quadrennial examinations. Age-, sex-, and education-adjusted models were tested for each risk factor measured at each exam and within three adult age groups: early adults (ages 35 to 50, median 41), middle adults (ages 51 to 60, median 54), and late adults (ages 61 to 70, median 63.5). Mean follow-up periods for people in the early, middle, and late age groups were 35.2 years, 25.8 years, and 18.5 years, respectively.

The team reported that as participants grew older, they tended to have higher triglyceride and glucose levels, higher systolic and diastolic blood pressure, and lower HDL cholesterol levels. They also were more likely to be treated for diabetes, hypertension, and dyslipidemia. Incident Alzheimer's dementia was negatively associated with HDL cholesterol for every 15 mg/dL increase in early adulthood (Hazard Ratio [HR] 0.85) and in middle adulthood (HR 0.82). This association remained significant with a similar effect size in the middle adulthood group when adjusted for dyslipidemia treatment.

The analyses also showed: triglyceride levels were associated with Alzheimer's dementia only in the early adulthood group, before (HR 1.33) and after (HR 1.30) adjusting for dyslipidemia treatment. Blood glucose in middle adulthood was associated with Alzheimer's dementia per 15 mg/dL increase, before (HR 1.15) and after (HR 1.18) adjusting for diabetes treatment. Future development of Alzheimer's dementia was progressively higher and likely to occur earlier among people who had blood glucose in pre-diabetic (100 to 126 mg/dL) and diabetic (>126 mg/dL) ranges in early adulthood and middle adulthood.

The authors concluded that HDL-C, triglyceride, and glucose levels measured in early to middle adulthood are significantly associated with incident AD several decades later, which suggests that early intervention to maintain healthy HDL, triglyceride, and glucose levels may improve cognition and lower AD risk in addition to the benefits of promoting vascular and metabolic health. The study was published on March 23, 2022 in the journal Alzheimer's & Dementia.

Related Links:
Boston University School of Medicine

Gold Supplier
Vaginosis Test
VAGINAL PANEL REALTIME PCR KIT
New
Fecal Occult Blood Test
iFOB Assay
New
Automated Clinical Chemistry Analyzer
DRI-CHEM NX600
New
Albumin Urine Test
Micro-Albumin ELISA

Print article
SUGENTECH INC.

Channels

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.